Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia
Sponsor: Pronova BioPharma
Terminated
This trial was terminated. No reason was provided.
Listed as NCT01972178, this PHASE2 trial focuses on Dyslipidemia and remains terminated or withdrawn. Sponsored by Pronova BioPharma, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)6-8 weeks screening period with diet/lifestyle stabilization and lipid qualification
6-8 weeks screening period with diet/lifestyle stabilization and lipid qualification
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pronova BioPharma
For direct contact, visit the study record on ClinicalTrials.gov .